Cover Image

Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease

Recent in-vitro studies indicate that estrogens such as 17β-estradiol (E2) may decrease the production of β-amyloid 1-42 (Aβ42), a peptide central for the formation of senile plaques in Alzheimer's disease (AD). To test this hypothesis in a clinical study, cerebrospinal fluid levels of E2 were...

Full description

Saved in:
Bibliographic Details
Main Authors: Schönknecht, Peter (Author) , Pantel, Johannes (Author) , Klinga, Klaus (Author) , Jensen, Malene (Author) , Hartmann, Tobias (Author) , Salbach, Birgit (Author) , Schröder, Johannes (Author)
Format: Article (Journal)
Language:English
Published: 20 June 2001
In: Neuroscience letters
Year: 2001, Volume: 307, Issue: 2, Pages: 122-124
ISSN:1872-7972
DOI:10.1016/S0304-3940(01)01896-1
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S0304-3940(01)01896-1
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0304394001018961
Get full text
Author Notes:Peter Schönknecht, Johannes Pantel, Klaus Klinga, Malene Jensen, Tobias Hartmann, Birgit Salbach, Johannes Schröder
Description
Summary:Recent in-vitro studies indicate that estrogens such as 17β-estradiol (E2) may decrease the production of β-amyloid 1-42 (Aβ42), a peptide central for the formation of senile plaques in Alzheimer's disease (AD). To test this hypothesis in a clinical study, cerebrospinal fluid levels of E2 were compared between 30 female AD patients and 11 female patients with non-dementing diseases such as major depression and investigated with respect to β-amyloid 1-40 and Aβ42 levels. E2 levels were significantly (P<0.05) lower in the AD group than in controls; within the AD group E2 levels were inversely correlated with Aβ42 concentrations (r=−0.36, P=0.05). This is the first clinical study providing evidence for an influence of E2 on Aβ42 metabolism in vivo. This observation corresponds to the putative beneficial effects of estrogen replacement therapy on the development and course of AD.
Item Description:Gesehen am 02.02.2021
Physical Description:Online Resource
ISSN:1872-7972
DOI:10.1016/S0304-3940(01)01896-1

Similar Items